3-Methyl-1-[(1-methylethyl)thio]-2-butanone | 256353-82-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Methyl-1-[(1-methylethyl)thio]-2-butanone
• 英文别名: 3-methyl-1-propan-2-ylsulfanylbutan-2-one
• CAS: 256353-82-9
• 化学式: C₈H₁₆OS
• 分子量: 160.28
• InChiKey: JUHZGSVZYKYLRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-diazo-3-methylbutan-2-one 、 异丙硫醇 在 二(三苯基膦)环戊二烯基氯化钌(II) 作用下， 以 氘代氯仿 为溶剂， 以94%的产率得到3-Methyl-1-[(1-methylethyl)thio]-2-butanone
  参考文献：
  名称：

  Del Zotto, Alessandro; Baratta, Walter; Rigo, Pierluigi, Journal of the Chemical Society. Perkin transactions I, 1999, # 21, p. 3079 - 3082

  摘要：

  DOI：

文献信息

• CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
  申请人：Fresenius Kabi Deutschland GmbH

  公开号：US20150297738A1

  公开（公告）日：2015-10-22

  The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS′(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

  本发明涉及一种羟烷基淀粉共轭物及其制备方法，所述羟烷基淀粉共轭物包括羟烷基淀粉衍生物和细胞毒性药剂，所述细胞毒性药剂包括至少一个次级羟基，其中羟烷基淀粉通过所述次级羟基与细胞毒性药剂连接。根据本发明的共轭物具有以下公式HAS'(-L-M)n的结构，其中M是细胞毒性药剂的残基，L是连接基团，HAS'是羟烷基淀粉衍生物的残基，n大于或等于1，且羟烷基淀粉衍生物的平均分子量（MW）高于肾脏阈值。
• Methods of using MEK inhibitors
  申请人：Lamb Peter

  公开号：US20080166359A1

  公开（公告）日：2008-07-10

  The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

  本发明提供了一种通过给予I式化合物或其药学上可接受的盐或溶剂与其他癌症治疗相结合的方法来治疗癌症的方法。
• c-MET MODULATORS AND METHODS OF USE
  申请人：BANNEN LYNNE CANNE

  公开号：US20090105299A1

  公开（公告）日：2009-04-23

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了一种用于调节蛋白激酶酶活性，以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学侵袭的化合物。更具体地，本发明提供了喹唑啉和喹啉，它们抑制、调节和/或调节激酶受体，特别是c-Met、KDF、c-Kit、flt-3和flt-4，与上述细胞活动变化相关的信号转导通路，包含这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供了制备上述化合物的方法和包含这些化合物的组合物。
• HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY
  申请人：SUTRO BIOPHARMA, INC.

  公开号：US20160257709A1

  公开（公告）日：2016-09-08

  Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W 1 , W 4 , W 5 , SG, and R are as described herein.

  本文提供了半天然菌素衍生物及其共轭物，包含这些衍生物或共轭物的组合物，制备这些衍生物和共轭物的方法，以及使用这些衍生物，共轭物和组合物治疗细胞增殖的方法。这些衍生物，共轭物和组合物在治疗和预防细胞增殖和癌症的方法中有用，用于细胞增殖和癌症的检测方法以及细胞增殖和癌症的诊断方法。在一个实施例中，半天然菌素衍生物如公式1000所示：或其药学上可接受的盐，溶剂或互变异构体，其中Ar，L，W1，W4，W5，SG和R如本文所述。
• Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release
  申请人：Lee S. Paul

  公开号：US20080306030A1

  公开（公告）日：2008-12-11

  The present invention is directed to methods of enhancing insulin release, GLP-1 release, and insulin sensitivity, methods of increasing insulin gene expression, methods of decreasing gastric secretion and emptying and glucagons secretion, and methods of inhibiting food intake, and methods of treating diabetes mellitus, insulin resistance syndrome, hyperglycemia, and obesity comprising administering to a subject an effective amount of a TRPM5 inhibitor.